Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis.
Rheumatol Int
; 28(1): 47-9, 2007 Nov.
Article
em En
| MEDLINE
| ID: mdl-17564711
ABSTRACT
Etanercept and infliximab treatments are often associated with autoantibodies induction. Their reported prevalences vary among different studies and the conclusions are somehow conflicting, mainly regarding whether the two drugs induce the same modifications. In this small prospective study, specifically designed to identify transient phenomena, we assess the prevalence of different relevant rheumatologic autoantibodies during anti-TNF-alpha courses in patients with rheumatoid arthritis. We report that both etanercept and infliximab transiently induce anti-DNA antibodies in 50-78% of patients, respectively, and these antibodies seem to be different from the typical lupus associated ones. Antinuclear antibodies (ANA) increased their titres and were newly produced up to 100% of patients. No other relevant antibodies are affected. Finally, as also confirmed for the first time by the patients switched from one drug to the other, the two TNF-alpha blockers behave similarly.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Artrite Reumatoide
/
Autoanticorpos
/
Imunoglobulina G
/
Receptores do Fator de Necrose Tumoral
/
Antirreumáticos
/
Anticorpos Monoclonais
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Rheumatol Int
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
Itália